Director Declaration

RNS Number : 9156C

Venn Life Sciences Holdings PLC

21 March 2014

 

21 March 2014

Venn Life Sciences Holdings Plc

("Venn" or the "Company")

Change of Board

Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces that Paul Foulger, Finance Director, has given notice of his intention to resign from the Board with effect from 14 April 2014, to pursue a fulltime role within another public Company. It is the intention of the Board to appoint a qualified finance director as soon as a suitable candidate has been identified.

The Board takes this opportunity to wish Paul every success in his new role.

Enquiries:

Venn Life Sciences Holdings Plc.
Tony Richardson, Chief Executive Officer	Tel: [phone]
Paul Foulger, Finance Director	Tel: [phone]
Orla McGuinness, Marketing Manager	Tel: [phone]
Zeus Capital (Nominated Adviser and Broker)
Ross Andrews/Andrew Jones (Corporate Finance)	Tel: [phone]
John Goold/Dominic Wilson/Alex Davies (Institutional Sales)		Tel: [phone]
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Paul McManus	Mob: [phone]
Lianne Cawthorne	Mob: [phone]

Additional Information:

About Venn Life Sciences Limited: www.vennlifesciences.com

Venn Life Sciences is a Clinical Research Organisation ("CRO") providing a suite of clinical trial management services to pharmaceutical, biotechnology and medical device organisations. With operations in France, Germany, Ireland, the Netherlands, Russia, the UK, and a branch office in Switzerland, the Venn Group also includes a Clinical Resourcing business placing experienced clinical teams and individuals on projects throughout Europe.  The company's near term objectives are the expansion of its CRO business throughout Europe, whilst enhancing the portfolio of their innovative technologies division, InnoVenn, with ground breaking new products and services.

 

END

 

 

RDNPGURPWUPCGWG